A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
Study sponsor: Alector Inc. · ALEC
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2024-08-19Actual
Enrollment · participants356Actual
Source updated2025-10-29Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.